Tesamorelin + Ipamorelin Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 8 to 12 weeks on, 4 to 8 weeks off (a 3-month on, 2-month off structure is common in clinic-style protocols)
• Frequency: Once nightly on a 5-days-on, 2-days-off weekly schedule
• Common delivery routes: Subcutaneous injection (lower abdomen, outer thigh, or back of upper arm; sites rotated each session)
• Key timing notes: Inject 30 to 90 minutes before sleep; fast for at least 2 to 3 hours beforehand; elevated insulin at injection time blunts the GH response

Who This Protocol Is For

The tesamorelin and ipamorelin stack draws a specific kind of user: someone who has already thought carefully about growth hormone optimization and wants a cleaner, more targeted approach. Where older GH secretagogue stacks relied on compounds that spiked cortisol, disrupted appetite, or required constant dose adjustment, this combination avoids most of those trade-offs because ipamorelin is notably selective for GH release without meaningfully affecting other hormonal axes.

The two most consistent goals people bring to this protocol are visceral fat reduction and body recomposition, often together. Tesamorelin has the deepest published record of any peptide for abdominal fat reduction, and ipamorelin's addition smooths GH pulse delivery and extends the fat-loss effect without adding meaningful side-effect burden. People who have hit a stubborn plateau with diet and training, particularly around the midsection, show up most frequently across both clinic and community protocol data for this stack.

A second group approaches it from a metabolic health angle: improved insulin sensitivity, better lipid profiles, and the longer-arc benefits of sustained GH optimization. A third group uses it for recovery and performance, including enhanced muscle repair, improved sleep quality, and body composition shifts over a full cycle.

Experience level shapes how the protocol is structured. Someone new to peptide therapy starts at the acclimation dose and takes the full four weeks before stepping up. Someone with prior GH secretagogue experience may enter closer to the target dose range from the beginning, though the graduated approach remains the standard for this stack. Delivery for this protocol is subcutaneous injection; there is no credible alternative route for achieving systemic GH effects with either of these peptides.

Active cancer, a pituitary disorder, pregnancy, or recent head surgery or radiation are contraindications. People with diabetes or pre-diabetes should approach this stack with close medical supervision given tesamorelin's potential to affect blood glucose.

How Is a Tesamorelin and Ipamorelin Cycle Structured?

The architecture of this protocol is a graduated two-phase cycle followed by a structured off period. Think of it less like flipping a switch and more like tuning an instrument: the first phase gets the system calibrated at a lower combined dose, and the second phase holds the target dose long enough for meaningful body composition changes to accumulate.

The acclimation phase covers roughly the first four weeks. During this period, the body adjusts to dual-pathway GH stimulation at a lower combined dose before stepping up. From week five onward, the protocol moves into the maintenance phase at the target dose, where most of the measurable results tend to appear. The Loading and Maintenance Phases section covers the phase mechanics in full detail.

A standard full cycle runs 8 to 12 weeks, with clinic-style protocols often structured as exactly 12 weeks on. This is followed by a break of at least four weeks, commonly eight weeks, before the next cycle begins. The off period is a designed feature of the protocol, not an optional precaution, for reasons the Off-Cycle Considerations section addresses directly.

How Your Dose Is Determined

What moves a tesamorelin and ipamorelin dose:

• Your goal: Visceral fat reduction and metabolic health goals sit at the center of this stack's use. The combined dose for those goals tends to run higher through the maintenance phase than during acclimation. Recovery and sleep-quality goals, where the emphasis is on optimizing GH pulse quality rather than maximizing fat oxidation, often sit comfortably in the lower to mid portion of the range. The ratio between tesamorelin and ipamorelin can also shift by goal: some clinic protocols weight tesamorelin more heavily for aggressive visceral fat reduction, while others use a closer to equal split throughout.

• Experience level: Someone new to GH secretagogues takes the full four-week acclimation period before stepping up, regardless of how quickly early effects appear. More experienced users who have run GH-axis peptides before may move through acclimation faster or enter closer to the target dose range from day one, though the graduated approach is still the standard for this stack.

• Tesamorelin-to-ipamorelin ratio: Because two distinct peptides are involved, the ratio between them is itself a dose variable. Tesamorelin has a GHRH receptor saturation point above which additional tesamorelin yields only marginally more GH output. The combination allows the tesamorelin component to stay below that ceiling while ipamorelin contributes through the ghrelin receptor pathway, producing a synergistic GH pulse that neither peptide generates alone. How that ratio is split depends on the goal and individual response.

• Individual response: Two people with identical goals and body composition can respond differently to the same combined dose. Water retention is one of the most variable early responses, attributed primarily to the tesamorelin component. IGF-1 levels measured mid-cycle, around week six, are the clearest objective signal of whether the dose is producing the intended GH effect.

There is no fixed dose that fits this stack for everyone. The combination of two peptides acting on distinct receptor pathways means the interaction adds a layer of variability beyond what either peptide creates alone. The acclimation-to-maintenance step-up exists partly because of this: it allows the dose to find its effect before committing to the target range.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal (visceral fat reduction, body recomposition, or metabolic health), your experience with GH secretagogues, and your preferred tesamorelin-to-ipamorelin ratio and builds your tesamorelin and ipamorelin protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take Tesamorelin and Ipamorelin?

The standard for this stack is once nightly, and the timing is specific for a reason. The body releases growth hormone in its largest natural pulses during deep sleep. Dosing 30 to 90 minutes before lights out means the GH secretagogue signal arrives just as the nocturnal pulse is building, amplifying it rather than creating a separate out-of-phase pulse. Morning injection is one of the most consistently flagged mistakes in practitioner and community protocol data precisely because it misses this window entirely.

The weekly schedule adds another layer of intentionality. Most protocols use five days on and two days off each week, typically Monday through Friday with weekend rest days. Continuous daily stimulation of both GHRH and ghrelin receptors across many weeks increases the risk of receptor desensitization; the two rest days per week preserve receptor sensitivity in a way that uninterrupted daily dosing does not across a full 8 to 12 week cycle.

The pre-injection fasting window matters just as much as the timing. Elevated insulin at the time of injection blunts the GH response to both peptides. A fast of at least 2 to 3 hours before injection, avoiding late snacks and alcohol, is the standard protocol recommendation and appears consistently across both practitioner and community reports.

Loading and Maintenance Phases

The acclimation and maintenance structure of this protocol is one of its most important design features. Understanding what each phase accomplishes explains why shortcuts here tend to backfire.

The acclimation phase covers roughly weeks one through four. It uses a lower combined dose not as an arbitrary warm-up, but because introducing dual-pathway GH stimulation at full target levels from day one meaningfully increases the likelihood of early side effects: water retention, joint stiffness, and flu-like onset symptoms. A blunted receptor response when the dose steps up is also a real risk. Starting lower allows the pituitary and related receptor systems to adjust gradually to the new stimulation pattern. The dose stays consistent throughout the four-week acclimation period; it is not escalated week by week within it.

From week five onward, the protocol moves to the target dose, the maintenance phase that runs for the remainder of the active cycle. This is where clinical and community data converge on meaningful results: visceral fat reduction becomes measurable, IGF-1 levels sustain their elevation, and body composition shifts become visible. The dose holds steady through maintenance as well. The step-up happens once, between acclimation and maintenance, and then the protocol holds at the target.

One detail specific to this combination: tesamorelin has a GHRH receptor saturation point above which additional tesamorelin yields only marginally more GH while multiplying cost and side-effect exposure. Because ipamorelin contributes through the ghrelin receptor pathway, the combination produces a synergistic GH pulse at lower individual component doses than tesamorelin would require alone. The maintenance-phase dose is structured around this practical ceiling. Some clinic-style protocols use an asymmetric ratio, weighting tesamorelin more heavily through maintenance for goals centered on visceral fat reduction. Others use a closer to equal split throughout.

Off-Cycle Considerations

Breaks are not optional with this stack. They are a designed feature of the protocol, not a precaution to be skipped when results are going well.

The primary reason is tachyphylaxis, the diminishing response to repeated receptor stimulation over time. Sustained, uninterrupted activation of GHRH receptors across many weeks reduces their sensitivity until the same dose produces less effect. The protocol ends up running at maintenance cost with declining returns. A structured break resets receptor sensitivity and restores the dose-response relationship for the next cycle.

The second concern is immunogenicity. Tesamorelin carries a risk of antibody formation with continuous long-term use, which is one reason the clinical indication involves medical monitoring. Cycling reduces exposure duration and the likelihood of a significant antibody response building up.

The standard break for an 8 to 12 week cycle is four to eight weeks off. Clinic-style three-month protocols typically call for a full two-month break before restarting. The minimum across community and practitioner data is one month, and most experienced users describe two months as the more reliable reset for IGF-1 levels to return to baseline before the next cycle begins.

Ipamorelin is more forgiving on its own: it does not suppress natural GH production, and some practitioners run it in longer continuous windows. But because this is a stack, the tesamorelin component governs the off-cycle structure. The break schedule is built around tesamorelin's properties, and ipamorelin follows along.

What to Expect Week by Week

• Week 1 to 2: The most commonly reported early effects are improved sleep depth and a sense of feeling warmer at night, both consistent with GH pulse amplification during the nocturnal window. Some users notice mild water retention or joint tightness as the body adjusts to dual-pathway stimulation during acclimation. Dramatic visible changes are not typical this early.

• Week 3 to 4: Muscle recovery between training sessions often improves noticeably here. Some users report a visible reduction in abdominal tightness and early recomposition signs, where the waistline feels different even when scale weight has not shifted. This is the closing phase of acclimation, and the system is building toward the step-up.

• Week 5 to 6: This is the window community reports describe most consistently, often called the "switch." Users commonly report a noticeable shift in visceral fat distribution and a reduction in waist circumference visible even when scale weight stays stable. IGF-1 levels measured at this point are typically elevated in responsive users.

• Week 7 to 12: The full maintenance phase is where the protocol delivers its best results. Across published tesamorelin research and community protocol reports, visceral fat reduction over a complete cycle is commonly in the range of 15 to 20 percent, alongside measurable improvements in lipid profiles and insulin sensitivity, continued muscle definition gains, and sustained sleep and energy improvements.

A well-run cycle through this window commonly produces body composition changes visible not just on a scale but in measurements and how clothes fit. The pattern that shows up across community logs for people who stay consistent with nightly timing, the pre-injection fasting window, adequate protein, and resistance training is a meaningful, progressive recomposition over the maintenance phase, with the most significant visceral fat shift landing between weeks five and eight. These timelines reflect what is commonly reported across published research and community protocol data; individual results vary based on adherence, training consistency, and individual metabolic factors. Water retention that appears early typically resolves within a few days of ending the cycle.

Common Protocol Mistakes

Injecting in the morning. This is the single most consistently flagged mistake in practitioner and community protocol data. The stack is designed to amplify the nocturnal GH pulse. Morning injection places the secretagogue signal at the wrong point in the biological rhythm. The correct timing is 30 to 90 minutes before sleep, every time.

Starting at the full target dose. Skipping the acclimation phase tends to produce excess water retention, joint discomfort, and sometimes a blunted receptor response when the higher maintenance dose is actually needed. The graduated structure exists because the two-peptide combination produces a stronger GH stimulus than either peptide alone, and the body needs time to adjust before it can respond optimally at the target level.

Eating or drinking before the injection. Elevated insulin at the time of injection competes with GH signaling and meaningfully reduces the effectiveness of both peptides. The 2 to 3 hour pre-injection fast is not a minor detail; it is a pharmacological requirement for the protocol to work as intended. Late snacks, alcohol, and high-sugar foods in the hours before injection are the most common versions of this mistake.

Dosing every day without rest days. Continuous daily stimulation of GHRH and ghrelin receptors without the structured two-day weekly break increases the risk of receptor desensitization across a full cycle. The 5-on, 2-off weekly schedule is the standard for this stack.

Doubling a missed dose. Tesamorelin's mechanism depends on consistent pulsatile signaling. Doubling a dose to compensate for a missed injection does not restore the missed signal; it disrupts the pattern without producing the intended benefit. Skip the missed dose and resume the normal schedule the next injection day.

Not rotating injection sites. Using the same site repeatedly leads to localized tissue changes that affect absorption. Rotating between the lower abdomen, outer thigh, and back of the upper arm maintains consistent absorption across the cycle.

Sourcing without verification. This stack involves two peptides with specific molecular identities. Sourcing from suppliers who cannot demonstrate third-party testing and manufacturing traceability introduces real risk of inaccurate labeling, impurities, or contamination. The FDA has flagged compounded peptides of uncertain origin as a safety concern. Traceable, third-party tested sourcing is not optional for a protocol run over 8 to 12 weeks.

The tesamorelin and ipamorelin combination is not FDA-approved for the off-label use described in this article; tesamorelin alone carries FDA approval only for HIV-associated lipodystrophy, and ipamorelin holds no FDA approval for any indication. GH-stimulating peptides are generally prohibited under WADA rules for tested athletes.

Frequently Asked Questions

How long is a typical tesamorelin and ipamorelin cycle?

Most protocols run 8 to 12 weeks, with a common clinic-style structure of 12 weeks on followed by a two-month break. Shorter cycles of 8 weeks with a 4 to 6 week break are used by beginners or those running the stack for the first time. The exact cycle length for your goals and history is personalized through the MyPeptidePal Protocol Creator.

How often do you take tesamorelin and ipamorelin?

The standard is once nightly, 30 to 90 minutes before sleep, on a 5-days-on, 2-days-off weekly schedule. The nighttime timing is pharmacologically important: it aligns the GH secretagogue signal with the body's natural nocturnal growth hormone pulse. The two weekly rest days reduce the risk of receptor desensitization across a full cycle.

Does tesamorelin and ipamorelin need a loading phase?

Yes. The standard protocol begins with a four-week acclimation phase at a lower combined dose before stepping up to the target maintenance dose. This graduated structure reduces early side effects like water retention and joint stiffness, and allows the receptor systems to adjust to dual-pathway GH stimulation before the higher maintenance dose is introduced.

Do you need to cycle off tesamorelin and ipamorelin?

Yes, structured breaks are a required feature of this protocol. Tesamorelin carries risks of receptor tachyphylaxis and antibody formation with continuous use. The standard minimum break is four weeks; most practitioners recommend two months off after a three-month cycle, with IGF-1 reassessment before restarting.

What makes ipamorelin a better GHRP for this stack than older peptides like GHRP-6?

Ipamorelin is notably selective for GH release and does not significantly affect cortisol, prolactin, or appetite hormones, which are the main drawbacks of older GHRPs. This selectivity means the combination amplifies the GH signal through two receptor pathways without the cortisol spike or hunger disruption that GHRP-6 and similar compounds produce. The cleaner hormonal profile makes ipamorelin a more practical long-cycle partner for tesamorelin.

Why is tesamorelin combined with ipamorelin rather than used alone?

Tesamorelin acts on GHRH receptors; ipamorelin acts on ghrelin receptors. Because they work through distinct pathways, the combination produces a synergistic GH pulse greater than what either peptide generates on its own. The stack also allows the tesamorelin dose to stay below the receptor saturation ceiling, where additional tesamorelin yields only marginal GH gains, while ipamorelin fills the gap through the second pathway. The practical result is a stronger combined GH stimulus at lower individual doses.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for tesamorelin and ipamorelin in one place.